Medivation/Astellas Confident Xtandi Data Will PREVAIL With Urologists
The companies expect the demonstrated improvement in progression-free survival will be particularly compelling for urologists treating castrate-resistant prostate cancer in patients who have not started chemotherapy.
You may also be interested in...
The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
PharmAsia News brings highlights from Japan’s week of earnings presentations.